肺癌免疫治疗进入2.0时代了吗

Has lung cancer immunotherapy entered era 2.0

肺癌作为世界范围病死率最高的恶性肿瘤,除放疗、化疗及靶向治疗外,免疫治疗如今也占一席地位,成为不容忽视的治疗策略。随着更多临床和基础研究发表,新免疫时代的到来势不可挡。文章从免疫检查点抑制剂、精准筛选人群与耐药机制探索等方面进行介绍。

American Society of Clinical Oncology has named immunotherapy 2.0 as the advance of this year recently. This selection is based on the recognition of the amazing progress achieved by the immunotherapy agents. Lung cancer is the leading cause of cancer death worldwide. Immunotherapy, along with traditional treatment strategies such as chemotherapy, radiation therapy and targeted therapy, provides patients of lung cancer with more possibilities. The new era of immunotherapy seems irresistible.